Pfizer Inc
NYSE:PFE
Pfizer Inc
Treasury Stock
Pfizer Inc
Treasury Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Treasury Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pfizer Inc
NYSE:PFE
|
Treasury Stock
-$115B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-4%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Treasury Stock
-$75.9B
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-14%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Treasury Stock
-$43.6B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-10%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Treasury Stock
-$59.4B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-5%
|
|
|
Zoetis Inc
NYSE:ZTS
|
Treasury Stock
-$7.9B
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-66%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Treasury Stock
-$3.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
0%
|
|
Pfizer Inc
Glance View
Pfizer Inc., a name synonymous with pharmaceutical innovation, embarked on its journey in 1849 when German immigrants Charles Pfizer and Charles Erhart founded the company in Brooklyn, New York. Over the decades, the modest chemical business transformed into a titan of the pharmaceutical industry, delivering breakthroughs that have shaped modern medicine. The company operates through its robust engine of research and development, continually investing billions into discovering and bringing to market medications that address unmet medical needs. Spanning therapeutic areas such as oncology, vaccines, rare diseases, and cardiovascular and metabolic health, Pfizer's strategic focus ensures a diverse product pipeline that aligns with global health trends and challenges. The company's revenue model is predominantly driven by the development, marketing, and sale of its pharmaceutical products. Blockbuster drugs like Lipitor and recently, the COVID-19 vaccine developed in collaboration with BioNTech, have contributed significantly to its earnings. Pfizer's ability to maintain a strong balance between branded pharmaceuticals and generics allows it to effectively cater to both emerging markets and developed economies, while its strategic partnerships and acquisitions further bolster its reach and capabilities. The synergy of science and business acumen at Pfizer has made it not only a hub of medical innovation but also a formidable enterprise in the competitive landscape of healthcare.
See Also
What is Pfizer Inc's Treasury Stock?
Treasury Stock
-115B
USD
Based on the financial report for Mar 30, 2025, Pfizer Inc's Treasury Stock amounts to -115B USD.
What is Pfizer Inc's Treasury Stock growth rate?
Treasury Stock CAGR 10Y
-4%
Over the last year, the Treasury Stock growth was 0%.
You don't have any saved screeners yet